| abstract |
The invention relates to the use of at least one active agent from the following group: 17 alpha -estradiol, its chemically modified derivatives and chemically modified derivatives of 17 beta -estradiol or estriol; for producing pharmaceutical preparations for treating side effects such as hot flushes during and/or after a treatment with analogs or antagonists of the gonadotropin-releasing hormone (GnRHa-therapy). Said pharmaceutical preparations can be produced in oral and parenteral, including topical, rectal, sub-cutaneous, intravenous, intramuscular, intraperitoneal, intranasal, intravaginal, intrabuccal or sub-lingual forms of administration. |